366 related articles for article (PubMed ID: 36672829)
1.
Trajković J; Makevic V; Pesic M; Pavković-Lučić S; Milojevic S; Cvjetkovic S; Hagerman R; Budimirovic DB; Protic D
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672829
[TBL] [Abstract][Full Text] [Related]
2. Bisphenol F affects neurodevelopmental gene expression, mushroom body development, and behavior in Drosophila melanogaster.
Fishburn JLA; Larson HL; Nguyen A; Welch CJ; Moore T; Penn A; Newman J; Mangino A; Widman E; Ghobashy R; Witherspoon J; Lee W; Mulligan KA
Neurotoxicol Teratol; 2024; 102():107331. PubMed ID: 38301979
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome.
Todd PK; Oh SY; Krans A; Pandey UB; Di Prospero NA; Min KT; Taylor JP; Paulson HL
PLoS Genet; 2010 Dec; 6(12):e1001240. PubMed ID: 21170301
[TBL] [Abstract][Full Text] [Related]
4. High functioning male with fragile X syndrome and fragile X-associated tremor/ataxia syndrome.
Basuta K; Schneider A; Gane L; Polussa J; Woodruff B; Pretto D; Hagerman R; Tassone F
Am J Med Genet A; 2015 Sep; 167A(9):2154-61. PubMed ID: 25920745
[TBL] [Abstract][Full Text] [Related]
5. Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model.
Monyak RE; Emerson D; Schoenfeld BP; Zheng X; Chambers DB; Rosenfelt C; Langer S; Hinchey P; Choi CH; McDonald TV; Bolduc FV; Sehgal A; McBride SMJ; Jongens TA
Mol Psychiatry; 2017 Aug; 22(8):1140-1148. PubMed ID: 27090306
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.
Sheridan SD; Theriault KM; Reis SA; Zhou F; Madison JM; Daheron L; Loring JF; Haggarty SJ
PLoS One; 2011; 6(10):e26203. PubMed ID: 22022567
[TBL] [Abstract][Full Text] [Related]
7. FMRP ribonucleoprotein complexes and RNA homeostasis.
Suardi GAM; Haddad LA
Adv Genet; 2020; 105():95-136. PubMed ID: 32560791
[TBL] [Abstract][Full Text] [Related]
8. CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.
Ludwig AL; Espinal GM; Pretto DI; Jamal AL; Arque G; Tassone F; Berman RF; Hagerman PJ
Hum Mol Genet; 2014 Jun; 23(12):3228-38. PubMed ID: 24463622
[TBL] [Abstract][Full Text] [Related]
9. Neuron-Specific FMRP Roles in Experience-Dependent Remodeling of Olfactory Brain Innervation during an Early-Life Critical Period.
Golovin RM; Vest J; Broadie K
J Neurosci; 2021 Feb; 41(6):1218-1241. PubMed ID: 33402421
[TBL] [Abstract][Full Text] [Related]
10. Wnd/DLK Is a Critical Target of FMRP Responsible for Neurodevelopmental and Behavior Defects in the Drosophila Model of Fragile X Syndrome.
Russo A; DiAntonio A
Cell Rep; 2019 Sep; 28(10):2581-2593.e5. PubMed ID: 31484070
[TBL] [Abstract][Full Text] [Related]
11. Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.
Santos AR; Kanellopoulos AK; Bagni C
Learn Mem; 2014 Oct; 21(10):543-55. PubMed ID: 25227249
[TBL] [Abstract][Full Text] [Related]
12. Unstable mutations in the FMR1 gene and the phenotypes.
Loesch D; Hagerman R
Adv Exp Med Biol; 2012; 769():78-114. PubMed ID: 23560306
[TBL] [Abstract][Full Text] [Related]
13. Fragile X syndrome and fragile X-associated tremor ataxia syndrome.
Hall DA; Berry-Kravis E
Handb Clin Neurol; 2018; 147():377-391. PubMed ID: 29325626
[TBL] [Abstract][Full Text] [Related]
14. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase.
Siller SS; Broadie K
Dis Model Mech; 2011 Sep; 4(5):673-85. PubMed ID: 21669931
[TBL] [Abstract][Full Text] [Related]
15. [Fragile X syndrome and FMR1-dependent diseases - clinical presentation, epidemiology and molecular background].
Landowska A; Rzońca S; Bal J; Gos M
Dev Period Med; 2018; 22(1):14-21. PubMed ID: 29641417
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic variability to medication management: an update on fragile X syndrome.
Elhawary NA; AlJahdali IA; Abumansour IS; Azher ZA; Falemban AH; Madani WM; Alosaimi W; Alghamdi G; Sindi IA
Hum Genomics; 2023 Jul; 17(1):60. PubMed ID: 37420260
[TBL] [Abstract][Full Text] [Related]
17. In vivo neuronal function of the fragile X mental retardation protein is regulated by phosphorylation.
Coffee RL; Williamson AJ; Adkins CM; Gray MC; Page TL; Broadie K
Hum Mol Genet; 2012 Feb; 21(4):900-15. PubMed ID: 22080836
[TBL] [Abstract][Full Text] [Related]
18. The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology.
Grigsby J
Clin Neuropsychol; 2016 Aug; 30(6):815-33. PubMed ID: 27356167
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous motor-behavior abnormalities in two
Andrew DR; Moe ME; Chen D; Tello JA; Doser RL; Conner WE; Ghuman JK; Restifo LL
J Neurogenet; 2021 Mar; 35(1):1-22. PubMed ID: 33164597
[TBL] [Abstract][Full Text] [Related]
20. Clinical, molecular, and pharmacological aspects of FMR1 related disorders.
Pugin A; Faundes V; Santa María L; Curotto B; Aliaga S; Salas I; Soto P; Bravo P; Peña MI; Alliende MA
Neurologia; 2017 May; 32(4):241-252. PubMed ID: 25529181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
